# Sava Technologies secures $19m to advance pain-free glucose biosensor with 10-day accuracy



London-based health tech startup Sava Technologies has secured $19 million in Series A funding after reporting promising early results from its pre-pivotal clinical trial of a next-generation wearable biosensor. Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, Sava is developing a proprietary multi-molecule biosensor designed to detect biomarkers just beneath the skin in real time. The device aims to offer a pain-free, affordable, and scalable alternative to current continuous glucose monitors (CGMs), which commonly face limitations around cost, invasiveness, and the duration of accurate sensor readings.

The latest clinical trial, conducted independently across sites in Oxford and Cambridge, enrolled 50 patients with Type 1 and insulin-dependent Type 2 diabetes. Early data from the first 25 participants demonstrated that Sava’s wearable delivered accurate and reliable glucose readings continuously for up to 10 days — a significant advancement compared to existing microsensor platforms, which typically struggle to maintain accuracy beyond 24 hours and rarely last more than five days. The trial was developed with input from leading diabetes clinicians and regulators, laying critical groundwork for regulatory submissions and a pivotal study planned for launch next year.

Rafaël Michali, co-founder and co-CEO of Sava, described the trial as a pivotal moment with the potential to redefine biosensing and personalised healthcare. He highlighted that their technology could match the performance of leading CGMs without the invasiveness or high costs associated with filament-based systems, opening new approaches to managing chronic diseases and more personalised health goals.

Sava’s innovation is targeted at overcoming key barriers hindering CGM adoption, including pain, expense, and limited accessibility. Currently, only about 1 percent of people with diabetes worldwide use CGMs, although this small group generates over $11 billion in annual global sales, growing at 10 percent annually. By delivering an affordable and pain-free device, Sava hopes to dramatically expand access and reshape diabetes management for millions who cannot afford or tolerate existing devices.

The $19 million Series A round was led by Balderton Capital and Pentland Ventures, with additional participation from Norrsken VC, JamJar Investments, True, Italian Founders Fund, Athletico Ventures, and Exceptional Ventures. James Wise, Partner at Balderton Capital, emphasised how Sava’s technology could democratise access not only to glucose monitoring but also to a wide range of biomarkers, expanding possibilities for preventive and personalised health management far beyond diabetes.

While glucose monitoring is Sava’s initial focus, its modular biosensor platform is designed for multi-analyte detection, enabling real-time tracking of various molecules. This versatility could attract athletes, health-conscious consumers, and others interested in optimising wellness, positioning Sava to enter the rapidly growing global wearables market, projected to exceed $100 billion by 2029. Co-founder Renato Circi noted that the platform will support multiple molecules in future iterations, creating new use cases across personalised healthcare.

Sava’s total funding now stands at $32 million, including earlier seed investments led by Balderton Capital and Exor Ventures. The seed round, announced in 2024, initially raised $8 million to develop the company’s revolutionary microneedle-based biosensor technology. This earlier funding supported foundational work on Sava’s microsensor capable of detecting molecules in interstitial fluid, as well as clinical validations and manufacturing scale-up plans.

The company has already achieved UK Medicines and Healthcare Products Regulatory Agency (MHRA) approvals for clinical trials, collaborating with prominent researchers at the Universities of Oxford and Cambridge. Beyond diabetes, Sava’s modular approach could monitor molecules like ketones, urea, proteins, allergens, or alcohol, unlocking new opportunities in chronic disease management, drug adherence, and wellbeing.

Pentland Ventures’ investor Charlie Rubin remarked that Sava, with its world-first technology and breakthrough clinical results, is well positioned to lead innovation in the multibillion-dollar global health wearables sector. The new funding will further grow Sava’s team, enhance automated manufacturing for target launch volumes, and accelerate clinical validation necessary to bring its microsensor technology to market.

As continuous glucose monitoring evolves, Sava’s platform promises a transformative step toward more accessible, painless, and personalised healthcare solutions. Its ability to extend sensor life and broaden biomarker detection highlights significant advancements over existing devices dominated by filament-based systems that remain costly and moderately invasive. If Sava successfully navigates regulatory pathways and commercial expansion, it could mark a milestone in preventative precision health, benefiting millions with diabetes and potentially revolutionising broader health monitoring.

### 📌 Reference Map:

* Paragraph 1 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[2]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)
* Paragraph 2 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[2]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)
* Paragraph 3 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/)
* Paragraph 4 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/)
* Paragraph 5 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/)
* Paragraph 6 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)
* Paragraph 7 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)
* Paragraph 8 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[3]](https://www.balderton.com/news/sava-raises-8m-to-build-preventative-personalised-precision-health-monitoring-at-scale/), [[4]](https://sifted.eu/articles/sava-raise-balderton), [[5]](https://bebeez.eu/2024/06/21/uk-startup-sava-raises-8m-to-develop-next-gen-continuous-glucose-monitor/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/), [[7]](https://www.bioworld.com/articles/709503-sava-raises-8m-for-minimally-invasive-transdermal-sensor)
* Paragraph 9 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)
* Paragraph 10 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)
* Paragraph 11 – [[1]](https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/), [[3]](https://www.balderton.com/news/sava-raises-8m-to-build-preventative-personalised-precision-health-monitoring-at-scale/), [[4]](https://sifted.eu/articles/sava-raise-balderton), [[6]](https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/)

Source: [Noah Wire Services](https://www.noahwire.com)

## Bibliography

1. <https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/> - Please view link - unable to able to access data
2. <https://tech.eu/2025/07/31/sava-raises-19m-series-a-following-breakthrough-clinical-biosensor-results/> - Sava Technologies, a London-based startup specialising in real-time molecular health monitoring, has secured $19 million in Series A funding. This investment follows promising early results from its pre-pivotal clinical trial, aiming to accelerate regulatory approval and commercialisation of its next-generation wearable device. Founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali, Sava has developed a proprietary multi-molecule biosensor capable of detecting biomarkers just beneath the skin in real time. Their first product is a pain-free wearable device that provides real-time molecular insights to a smartphone, offering a more affordable alternative to current solutions. The latest clinical trial, conducted across sites in Oxford and Cambridge, enrolled 50 patients with Type 1 and insulin-dependent Type 2 diabetes. Early results from the first 25 participants demonstrated that Sava’s technology delivered accurate and reliable glucose readings for up to 10 days of continuous use, a milestone unmatched by current microsensor platforms, which often struggle beyond 24 hours and rarely last more than five days. Designed in collaboration with leading diabetes clinicians and regulators, the trial lays a critical foundation for future regulatory submissions and Sava’s upcoming pivotal study, planned for launch next year.
3. <https://www.balderton.com/news/sava-raises-8m-to-build-preventative-personalised-precision-health-monitoring-at-scale/> - Sava Technologies has raised $8 million in a seed funding round led by Balderton Capital and Exor Ventures. The company is developing a multi-molecule biosensing wearable capable of detecting biomarkers just beneath the skin’s surface, enabled by its novel microsensing technology. Founded by bioengineers Renato Circi and Rafael Michali from Imperial College London, Sava aims to revolutionise health monitoring by making world-leading technology available to all. The funding will accelerate the goal of creating a new paradigm for healthcare—preventative, personalised, and painless. The wearable device is designed to detect molecules in the interstitial fluid, just under the skin, and deliver data directly to a user’s phone.
4. <https://sifted.eu/articles/sava-raise-balderton> - UK startup Sava has announced an $8 million seed round to develop the next generation of continuous glucose monitors (CGMs). The company is building a new type of CGM that is less invasive, cheaper, and capable of monitoring a wider range of chronic conditions and biomarkers. The funding, led by Balderton Capital and Exor Ventures, will be used to take Sava’s device through clinical trials and scale manufacturing capabilities. Sava’s CGM uses several smaller 1mm microneedles to measure glucose levels in the interstitial fluid, offering a less intimidating and more cost-effective alternative to current devices. The company plans to expand its device to monitor other molecules, such as ketones, urea, proteins, allergens, or alcohol, in the future.
5. <https://bebeez.eu/2024/06/21/uk-startup-sava-raises-8m-to-develop-next-gen-continuous-glucose-monitor/> - Sava Technologies has raised $8 million in a seed funding round led by Balderton Capital and Exor Ventures. The company is developing a new type of continuous glucose monitor (CGM) that is less invasive, cheaper, and capable of monitoring a wider range of chronic conditions and biomarkers. The funding will be used to take Sava’s device through clinical trials and scale manufacturing capabilities. Sava’s CGM uses several smaller 1mm microneedles to measure glucose levels in the interstitial fluid, offering a less intimidating and more cost-effective alternative to current devices. The company plans to expand its device to monitor other molecules, such as ketones, urea, proteins, allergens, or alcohol, in the future.
6. <https://thetimesmag.com/2024/06/21/sava-raises-e7-4-million-to-revolutionize-health-monitoring-with-groundbreaking-microsensor-technology/> - Sava Technologies has secured over €7.4 million in a seed funding round led by Balderton Capital and Exor Ventures. Founded by bioengineers Renato Circi and Rafael Michali from Imperial College London, Sava introduces a groundbreaking microsensing device designed to detect molecules in the interstitial fluid just beneath the skin. This technology is embedded within a smart, connected wearable patch that transmits real-time health data directly to a user’s mobile device. Sava’s flagship microsensor initially targets glucose monitoring for individuals with diabetes, a condition projected to affect over 783 million adults globally by 2045. The company has received approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for clinical trials and plans to collaborate with leading researchers from the Universities of Oxford and Cambridge. Beyond diabetes management, Sava’s modular design aims to enable simultaneous monitoring of multiple molecules, opening doors to monitoring chronic conditions, enhancing wellbeing applications, improving drug adherence, and personalising therapies, marking a shift towards preventative healthcare.
7. <https://www.bioworld.com/articles/709503-sava-raises-8m-for-minimally-invasive-transdermal-sensor> - Sava Technologies Ltd. has emerged from five years of stealth with $8 million in seed funding for its microneedle-based sensor. The financing round was led by Balderton Capital and Exor Ventures and will be used to expand the company’s team, design the next-generation product, and conduct clinical studies. Sava is developing a wearable biosensor platform for glucose monitoring in diabetics, delivering real-time health insights to a user's phone affordably and painlessly. The company aims to revolutionise health monitoring by making world-leading technology available to all, with a focus on preventative, personalised, and painless healthcare.